Cryoport (CYRX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 Jun, 2026Opening remarks and agenda
Meeting called to order by the Chair, with directors, executive officers, CFO, and independent auditors present.
Agenda and rules of conduct made available on the virtual meeting site and investor relations website.
Board and executive committee updates
Six directors nominated for election to serve a one-year term expiring at the 2027 Annual Meeting.
Shareholder proposals
Four management proposals presented: election of directors, ratification of independent auditor, advisory approval of executive compensation, and amendment to the equity incentive plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cryoport
- Q2 2026 revenue up 8% to $49M, adjusted EBITDA positive, and strong liquidity maintained.CYRX
Q2 2026 - Leading CGT supply chain provider projects strong growth, margin expansion, and digital integration.CYRX
Investor presentation - Global C> supply chain leader with 17 commercial therapies, $56.7M Q3 revenue, and rapid sector growth.CYRX
Investor presentation - 16% revenue growth and 70% CGT trial share highlight strong momentum and global expansion.CYRX
Corporate presentation - Q1 2026 revenue up 16–16.5%, guidance raised, and profitability expected in H2 2026.CYRX
Q1 2026 - Strong revenue growth, digital transformation, and key governance votes mark this year's proxy.CYRX
Proxy filing - FY2025 revenue rose 12% to $176.2M, with margin expansion and strong CGT market growth.CYRX
Q4 2025 - Q3 2024 revenue grew 1% as services outpaced products, margins improved, and guidance was reaffirmed.CYRX
Q3 2024 - Q2 2024 revenue hit $57.6M; strong cell therapy growth, $63.8M impairment, $22M cost savings targeted.CYRX
Q2 2024